Plain-English translation of NCT06359847 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing ST-1898, a new medication taken by mouth once daily, for people with advanced thyroid cancer that no longer responds to radioactive iodine treatment and has failed at least one prior drug therapy. The medication targets multiple proteins in cancer cells that help them grow and spread. The study wants to learn whether this treatment can slow or stop the cancer's progression and how well patients tolerate it.
Many people with advanced thyroid cancer eventually develop resistance to radioactive iodine and may not have effective options after their first drug treatment fails. This trial exists to see if this medication could offer a new treatment choice for these patients who have limited alternatives.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once daily in 3-week cycles, taking the pill for 14 days straight, then taking 7 days off before starting the next cycle. You would continue this pattern until your cancer stops responding to the treatment or you experience side effects you cannot tolerate. Throughout the study, you'll have regular clinic visits for blood tests, imaging scans to measure your tumor, and check-ins to monitor how you're doing and discuss any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China